The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
REGULATORY
Govt Deregulation Panel Calls for Revisiting 14-Day Prescription Limit
The government’s Regulatory Reform Council submitted a recommendation on June 16 calling for revising a 14-day prescription limit imposed on newly approved drugs during their first year on the market. Based on this recommendation, handed to Prime Minister Shinzo Abe,…
To read the full story
Related Article
- Deregulation Panel Calls for Revisiting Plasma Export Restrictions, Wants Conclusion by FY2018
May 20, 2016
- 14-Day Prescription Limit to Be Discussed toward Next Reform: MHLW Official
April 4, 2016
- Govt OKs Economic Growth Strategy, Regulatory Reform Plan
July 1, 2015
- MHLW to Launch Switch OTC Panel as Early as Summer
June 3, 2015
- Govt Panel to Prod Chuikyo to Revisit 14-Day Prescription Limit
April 17, 2015
- JPA Vice President Disagrees with Exclusion of OTC-Like Drugs from Insurance Coverage
April 13, 2015
- Set Ceiling for Health Coverage of OTC-Like Drugs: Govt Panel
April 9, 2015
- 1st Generation Poultices “Just One Example” for Proposal to Scrap Health Coverage for OTC-Like Drugs: Shirakawa
March 26, 2015
- Govt Panel Members Push Deregulation of Bungyo Rules
March 16, 2015
REGULATORY
- MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
- JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
March 14, 2025
- Chuikyo to Discuss Potential Pricing Steps to Deal with Higher Costs of Japan-Made APIs
March 13, 2025
- MHLW to Extend NIP Period for MR Vaccines by 2 Years amid Shortage
March 13, 2025
- Chuikyo Rep Calls for Proper Use of Zepbound, Frets Expansion of Obesity Market
March 13, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…